Background: Reduced eGFR is associated with increased risk of cardiovascular disease and mortality.

Methods: In a urological practice registry of 858 men with hypogonadism, 356 men (41.5%) had T2DM. 178 received TU 1000 mg every 12 weeks (T-group). 178 opted against treatment (CTRL). Changes over time between groups were compared and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the groups. eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.

Results: Mean follow-up 8.2±2.9, baseline age: 61.5±5.4 (T-group) and 63.7±4.9 years (CTRL). Creatinine decreased by 0.16±0.03 mg/dL at 11 years in the T-group and increased by 0.32±0.03 mg/dL in CTRL. Estimated adjusted difference between groups: -0.48 mg/dL (p<0.0001 for all). T-group: eGFR increased by 9.8±1.4 mL/min/1.73 m². The peak mean value was recorded in year 8 after which a small but steady decline occurred. CTRL: eGFR decreased progressively by 22.3±1.3 mL/min/1.73 m². Difference between groups: 32.2 mL/min/1.73 m² (p<0.0001 for all). Systolic blood pressure decreased in the T-group by 32.3±1.2 mmHg and increased in CTRL by 14.5±1.1 mmHg. Difference between groups: -46.8 mmHg (p<0.0001 for all). Diastolic blood pressure decreased in the T-group by 19.2±0.9 mmHg and increased in CTRL by 9.5±0.8 mmHg. Difference between groups: -28.7 mmHg (p<0.0001 for all). During the entire observation period, 13 deaths (7.3%) and no cardiovascular events occurred in the T-group. In CTRL, 48 deaths (27.0%), 55 cases of myocardial infarction (30.9%) and 45 cases of stroke (25.3%) were recorded. Nephropathy occurred in 0.6% in the T-group and in 4% in CTRL (p<0.05).

Conclusions: Long-term testosterone therapy in men with hypogonadism and T2DM prevents age-related deterioration in GFR.


K.S. Haider: None. A. Haider: None. F. Saad: Consultant; Self; Bayer AG. Stock/Shareholder; Self; AbbVie Inc., Bayer AG.


Bayer AG

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at